CAR T cell therapy for recurrent glioblastoma
Part of Brain & nervous system clinical trials.
This early-phase study tests a type of immune-cell treatment (CAR T cells) aimed at a target called B7-H3 in people with glioblastoma or related grade 4 brain tumors that have come back. It’s meant to see if the treatment can shrink the tumor or control the disease and to learn how safe it is.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed grade 4 brain tumor (glioblastoma or related types) that has come back or grown after standard treatment, and it’s been checked as IDH “wild-type.”
- Surgery is being considered because the tumor is thought to be mostly removable.
- You’re between 18 and 75 years old, and you can do day-to-day activities at least at a moderate level (Karnofsky score 60+).
- Steroid medicine for brain swelling is limited to 4 mg or less per day of Decadron (dexamethasone).
- Your blood counts and organ tests (kidney, liver, heart, oxygen level) meet study thresholds; you also must not have certain serious infections.
- You can travel to Stanford Health Care for frequent visits and are willing and able to sign informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial studies a personalized immune-cell treatment (CAR-T) for glioblastoma that has come back. It aims to shrink or control the regrowing brain tumor by using your own immune cells after processing them in a lab.
This trial tests a new type of immunotherapy called CAR T-cells that target a protein called GARP on your tumor cells. It is for people whose high-grade glioma (a fast-growing brain tumor) has come back after previous treatment.
This trial is testing a new type of cell therapy called CAR-T that targets a marker (B7-H3) on brain tumor cells. It is for people with grade 4 gliomas that have returned after standard treatment, and it aims to see if this treatment can help control the tumor.
This trial tests genetically engineered immune cells (CAR T cells) injected directly into the brain to treat recurring or worsening high-grade gliomas. The cells are designed to recognize and attack tumor cells that have specific markers (EGFR and IL13Rα2).
This trial tests a new treatment called CAR-T cell therapy for people whose glioblastoma (a type of brain tumor) has come back or not responded to standard care. The treatment uses your own immune cells (T cells) that are specially modified to attack tumor cells that show a marker called CD276.
This Phase 1 study tests a personalized immune-cell treatment (CAR-T) made from your own cells to attack a marker called B7-H3 on recurring glioblastoma. It may help shrink or control the tumor, but the main goal is to check safety and how the treatment works.
Hear when a new Brain and Nervous System trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.